Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5220652
Max Phase: Preclinical
Molecular Formula: C66H96IN19O21S4
Molecular Weight: 1746.78
Associated Items:
ID: ALA5220652
Max Phase: Preclinical
Molecular Formula: C66H96IN19O21S4
Molecular Weight: 1746.78
Associated Items:
Canonical SMILES: C[C@@H](O)[C@@H]1NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)c(I)c3)NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC1=O)C(C)(C)SSC(C)(C)[C@@H](NC(=O)CN)C(=O)N2
Standard InChI: InChI=1S/C66H96IN19O21S4/c1-30(87)48-58(101)79-39(26-47(92)93)61(104)86-22-8-11-43(86)57(100)76-36(9-6-20-73-63(70)71)53(96)85-50-60(103)77-35(10-7-21-74-64(72)107)51(94)78-38(25-32-14-18-44(89)34(67)23-32)54(97)75-37(17-19-45(69)90)52(95)81-41(55(98)80-40(62(105)106)24-31-12-15-33(88)16-13-31)28-108-109-29-42(56(99)84-48)82-59(102)49(83-46(91)27-68)65(2,3)110-111-66(50,4)5/h12-16,18,23,30,35-43,48-50,87-89H,6-11,17,19-22,24-29,68H2,1-5H3,(H2,69,90)(H,75,97)(H,76,100)(H,77,103)(H,78,94)(H,79,101)(H,80,98)(H,81,95)(H,82,102)(H,83,91)(H,84,99)(H,85,96)(H,92,93)(H,105,106)(H4,70,71,73)(H3,72,74,107)/t30-,35+,36+,37+,38+,39+,40+,41+,42+,43+,48+,49+,50-/m1/s1
Standard InChI Key: MXCGAVBCIMSYFN-GBYOZMAQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1746.78 | Molecular Weight (Monoisotopic): 1745.4956 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Gajewiak J, Christensen SB, Dowell C, Hararah F, Fisher F, Huynh PN, Olivera BM, McIntosh JM.. (2021) Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism., 64 (13.0): [PMID:34142837] [10.1021/acs.jmedchem.1c00512] |
Source(1):